Bodian 25 mg (Empagliflozin)

Adult dose

The recommended dose for this medication is 10 mg once daily for monotherapy and additional combination therapy with insulin and other blood sugar-lowering agents. If the patient tolerates this medication well and additional blood sugar control is needed, the dose may be increased to 25 mg once daily. This medication can be administered without regard to meals. The tablet should be swallowed whole. If a dose is missed, it should be taken as soon as remembered.

This medication should not be taken by those who are allergic to the active ingredient or any of the components. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, end-stage renal disease, or those undergoing dialysis should not take this medication. This medication contains lactose and may not be suitable for individuals with genetic issues like lactose intolerance or galactose malabsorption. Patients with slightly impaired kidney function may need dosage adjustments when taking this medication, and use should be discontinued if kidney function deteriorates further. Use with caution in patients with mild to moderate heart failure, and it is not recommended for patients with severe heart failure. There may be a risk of hypoglycemia when taken with other blood sugar-lowering agents such as insulin or sulfonylureas, so dosage adjustments may be necessary. While taking this medication, attention should be paid to potential symptoms such as hypoglycemia, genital and urinary tract infections, increased urination, and signs of dehydration. Particularly in elderly patients or those at risk of fluid loss, monitoring for dehydration and hypotension is important, and temporary discontinuation may be necessary. Serious metabolic abnormalities known as ketoacidosis may occur, and if symptoms are suspected, immediate consultation with a healthcare provider is required. This medication is not recommended during pregnancy, and it is advisable to avoid use while breastfeeding. The safety and efficacy in children and adolescents under 18 years have not been established. Caution is required when driving or operating machinery due to the risk of hypoglycemia. Rare side effects such as lower limb amputations or serious perineal infections have been reported with long-term use, making regular monitoring and observation important. There may be interactions with other medications, so inform your healthcare provider of any other drugs being taken. This medication should be kept out of reach of children and should not be transferred to other containers.

Serious side effects

• Urticaria
• angioedema
• ketoacidosis
• urosepsis and pyelonephritis
• perineal necrosis

Mild side effects

• Hypoglycemia
• vulvovaginitis
• vulvar vulvitis
• balanitis and other genital infections
• increased urination
• urinary tract infections
• fluid volume loss
• increased serum creatinine
• decreased glomerular filtration rate
• itching

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is advisable to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature to preserve the medication’s effectiveness.

Appearance

Pale yellow oval film-coated tablet

Package unit

PTP - 30 tablets/PTP [10 tablets/PTP x 3]